247 related articles for article (PubMed ID: 27648202)
1. Antifungal Therapy in Hematopoietic Stem Cell Transplant Recipients.
Busca A; Pagano L
Mediterr J Hematol Infect Dis; 2016; 8(1):e2016039. PubMed ID: 27648202
[TBL] [Abstract][Full Text] [Related]
2. Secondary antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients with invasive fungal infection.
Pepeler MS; Yildiz Ş; Yegin ZA; Özkurt ZN; Tunçcan ÖG; Erbaş G; Köktürk N; Kalkanci A; Yildirim Z
J Infect Dev Ctries; 2018 Sep; 12(9):799-805. PubMed ID: 31999640
[TBL] [Abstract][Full Text] [Related]
3. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry.
Neofytos D; Horn D; Anaissie E; Steinbach W; Olyaei A; Fishman J; Pfaller M; Chang C; Webster K; Marr K
Clin Infect Dis; 2009 Feb; 48(3):265-73. PubMed ID: 19115967
[TBL] [Abstract][Full Text] [Related]
4. Complications of hematopoietic stem transplantation: Fungal infections.
Omrani AS; Almaghrabi RS
Hematol Oncol Stem Cell Ther; 2017 Dec; 10(4):239-244. PubMed ID: 28636889
[TBL] [Abstract][Full Text] [Related]
5. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
Mellinghoff SC; Panse J; Alakel N; Behre G; Buchheidt D; Christopeit M; Hasenkamp J; Kiehl M; Koldehoff M; Krause SW; Lehners N; von Lilienfeld-Toal M; Löhnert AY; Maschmeyer G; Teschner D; Ullmann AJ; Penack O; Ruhnke M; Mayer K; Ostermann H; Wolf HH; Cornely OA
Ann Hematol; 2018 Feb; 97(2):197-207. PubMed ID: 29218389
[TBL] [Abstract][Full Text] [Related]
6. Systemic antifungal prophylaxis after hematopoietic stem cell transplantation: a meta-analysis.
Ziakas PD; Kourbeti IS; Mylonakis E
Clin Ther; 2014 Feb; 36(2):292-306.e1. PubMed ID: 24439393
[TBL] [Abstract][Full Text] [Related]
7. Treatment of invasive fungal infections in high risk hematological patients. The outcome with liposomal amphotericin B is not negatively affected by prior administration of mold-active azoles.
De la Serna J; Jarque I; López-Jiménez J; Fernández-Navarro JM; Gómez V; Jurado M; Pascual A; Serrano J; Romero M; Vallejo C
Rev Esp Quimioter; 2013 Mar; 26(1):64-9. PubMed ID: 23546466
[TBL] [Abstract][Full Text] [Related]
8. [Current approaches to diagnosis and treatment of invasive fungal infection in HSCT recipients].
Shao Q; Shen DX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Dec; 17(6):1619-23. PubMed ID: 20030960
[TBL] [Abstract][Full Text] [Related]
9. Antifungal prophylaxis in adult lung transplant recipients: Uncertainty despite 30 years of experience. A systematic review of the literature and network meta-analysis.
Marinelli T; Davoudi S; Foroutan F; Orchanian-Cheff A; Husain S
Transpl Infect Dis; 2022 Jun; 24(3):e13832. PubMed ID: 35388588
[TBL] [Abstract][Full Text] [Related]
10. Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies.
Candoni A; Mestroni R; Damiani D; Tiribelli M; Michelutti A; Silvestri F; Castelli M; Viale P; Fanin R
Eur J Haematol; 2005 Sep; 75(3):227-33. PubMed ID: 16104879
[TBL] [Abstract][Full Text] [Related]
11. Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients.
Park S; Kim K; Jang JH; Kim SJ; Kim WS; Chung DR; Kang CI; Peck KR; Jung CW
J Infect; 2016 Nov; 73(5):496-505. PubMed ID: 27394404
[TBL] [Abstract][Full Text] [Related]
12. Changing strategies for the management of invasive fungal infections.
Rapp RP
Pharmacotherapy; 2004 Feb; 24(2 Pt 2):4S-28S; quiz 29S-32S. PubMed ID: 14992487
[TBL] [Abstract][Full Text] [Related]
13. Prophylaxis for aspergillosis in patients with haematological malignancies: pros and cons.
Busca A; Pagano L
Expert Rev Anti Infect Ther; 2018 Jul; 16(7):531-542. PubMed ID: 30033822
[TBL] [Abstract][Full Text] [Related]
14. An update on the safety and interactions of antifungal drugs in stem cell transplant recipients.
Girmenia C; Iori AP
Expert Opin Drug Saf; 2017 Mar; 16(3):329-339. PubMed ID: 28004589
[TBL] [Abstract][Full Text] [Related]
15. Antifungal treatment strategies in high risk patients.
Rüping MJ; Vehreschild JJ; Cornely OA
Mycoses; 2008 Sep; 51 Suppl 2():46-51. PubMed ID: 18721331
[TBL] [Abstract][Full Text] [Related]
16. Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients: current issues and new agents.
Strasfeld L; Weinstock DM
Expert Rev Anti Infect Ther; 2006 Jun; 4(3):457-68. PubMed ID: 16771622
[TBL] [Abstract][Full Text] [Related]
17. Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients.
Bow EJ; Vanness DJ; Slavin M; Cordonnier C; Cornely OA; Marks DI; Pagliuca A; Solano C; Cragin L; Shaul AJ; Sorensen S; Chambers R; Kantecki M; Weinstein D; Schlamm H
BMC Infect Dis; 2015 Mar; 15():128. PubMed ID: 25887385
[TBL] [Abstract][Full Text] [Related]
18. Secondary antifungal prophylaxis in pediatric hematopoietic stem cell transplants.
Azik FM; Tezer H; Ozkaya-Parlakay A; Aksu T; Bayram C; Fettah A; Tavil B; Tunç B
J Pediatr Hematol Oncol; 2015 Jan; 37(1):e19-22. PubMed ID: 25522351
[TBL] [Abstract][Full Text] [Related]
19. Antifungal prophylaxis and therapy in patients with hematological malignancies and hematopoietic stem cell transplant recipients.
Almyroudis NG; Segal BH
Expert Rev Anti Infect Ther; 2010 Dec; 8(12):1451-66. PubMed ID: 21133669
[TBL] [Abstract][Full Text] [Related]
20. Long-term antifungal prophylaxis in high-risk hematopoietic stem cell transplant recipients.
Bow EJ
Med Mycol; 2005 May; 43 Suppl 1():S277-87. PubMed ID: 16110821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
